Pharvaris N.V.
PHVS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.31 | -0.61 | -0.08 | -0.14 |
| FCF Yield | -12.07% | -9.56% | -19.07% | -11.62% |
| EV / EBITDA | -4.95 | -6.02 | -2.21 | -3.25 |
| Quality | ||||
| ROIC | -54.98% | -25.48% | -58.46% | -32.17% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.91 | 0.93 | 0.89 | 1.05 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -29.56% | -38.42% | -50.43% | -107.63% |
| Safety | ||||
| Net Debt / EBITDA | 1.92 | 4.04 | 1.86 | 3.87 |
| Interest Coverage | 0.00 | 0.00 | -5,385.77 | -236.89 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.04 | 0.05 |
| Cash Conversion Cycle | 0.00 | -4,209.96 | -4,702.46 | -2,802.55 |